Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

An antibody-free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GST-HDM2 recombinant protein.

Costa B, Grillone AF, Salvetti A, Rocchiccioli S, Iacopetti P, Daniele S, Da Pozzo E, Campiglia P, Novellino E, Martini C, Rossi L.

Drug Test Anal. 2013 Jul;5(7):596-601. doi: 10.1002/dta.1492. Epub 2013 Jun 4.

PMID:
23733564
2.

A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions.

Lundholt BK, Heydorn A, Bjørn SP, Praestegaard M.

Assay Drug Dev Technol. 2006 Dec;4(6):679-88.

PMID:
17199506
3.

Small molecule inhibitors of the p53-MDM2.

Hu CQ, Hu YZ.

Curr Med Chem. 2008;15(17):1720-30. Review.

PMID:
18673221
4.

Molecular characterization of the hdm2-p53 interaction.

Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel HK, Sampson W, Ang K, Howard SF, Picksley SM, Lane DP.

J Mol Biol. 1997 Jun 27;269(5):744-56.

PMID:
9223638
5.

Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.

Noguchi T, Oishi S, Honda K, Kondoh Y, Saito T, Kubo T, Kaneda M, Ohno H, Osada H, Fujii N.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3802-5. doi: 10.1016/j.bmcl.2013.04.094. Epub 2013 May 15.

PMID:
23726030
6.

Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.

Dudgeon DD, Shinde S, Hua Y, Shun TY, Lazo JS, Strock CJ, Giuliano KA, Taylor DL, Johnston PA, Johnston PA.

J Biomol Screen. 2010 Aug;15(7):766-82. doi: 10.1177/1087057110375304. Epub 2010 Jul 16.

PMID:
20639499
7.

N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.

Hayashi R, Wang D, Hara T, Iera JA, Durell SR, Appella DH.

Bioorg Med Chem. 2009 Dec 1;17(23):7884-93. doi: 10.1016/j.bmc.2009.10.032. Epub 2009 Oct 21.

8.

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.

Patel S, Player MR.

Expert Opin Investig Drugs. 2008 Dec;17(12):1865-82. doi: 10.1517/13543780802493366 . Review.

PMID:
19012502
9.

The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.

Yurlova L, Derks M, Buchfellner A, Hickson I, Janssen M, Morrison D, Stansfield I, Brown CJ, Ghadessy FJ, Lane DP, Rothbauer U, Zolghadr K, Krausz E.

J Biomol Screen. 2014 Apr;19(4):516-25. doi: 10.1177/1087057113518067. Epub 2014 Jan 29.

PMID:
24476585
10.

Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.

Bandaru S, Ponnala D, Lakkaraju C, Bhukya CK, Shaheen U, Nayarisseri A.

Asian Pac J Cancer Prev. 2015;16(9):3759-65.

11.

Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

Dudgeon DD, Shinde SN, Shun TY, Lazo JS, Strock CJ, Giuliano KA, Taylor DL, Johnston PA, Johnston PA.

Assay Drug Dev Technol. 2010 Aug;8(4):437-58. doi: 10.1089/adt.2010.0281.

12.

Rapid screening of protein-protein interaction inhibitors using the protease exclusion assay.

Nirantar SR, Li X, Siau JW, Ghadessy FJ.

Biosens Bioelectron. 2014 Jun 15;56:250-7. doi: 10.1016/j.bios.2013.12.060. Epub 2014 Jan 17.

PMID:
24508816
13.

Identification and characterization of the first small molecule inhibitor of MDMX.

Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA.

J Biol Chem. 2010 Apr 2;285(14):10786-96. doi: 10.1074/jbc.M109.056747. Epub 2010 Jan 15.

14.

Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.

Geng QQ, Dong DF, Chen NZ, Wu YY, Li EX, Wang J, Wang SM.

Int J Oncol. 2013 Dec;43(6):1935-42. doi: 10.3892/ijo.2013.2138. Epub 2013 Oct 14.

PMID:
24126697
15.

A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction.

Li J, Zhang S, Gao L, Chen Y, Xie X.

J Biomol Screen. 2011 Apr;16(4):450-6. doi: 10.1177/1087057111399191.

PMID:
21471462
16.

Small molecule protein-protein inhibitors for the p53-MDM2 interaction.

Dudkina AS, Lindsley CW.

Curr Top Med Chem. 2007;7(10):952-60. Review.

PMID:
17508926
17.

Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.

Patil SP, Pacitti MF, Gilroy KS, Ruggiero JC, Griffin JD, Butera JJ, Notarfrancesco JM, Tran S, Stoddart JW.

J Comput Aided Mol Des. 2015 Feb;29(2):155-63. doi: 10.1007/s10822-014-9811-6. Epub 2014 Nov 7.

PMID:
25377899
18.

The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63.

Calabrò V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G.

J Biol Chem. 2002 Jan 25;277(4):2674-81. Epub 2001 Nov 19.

19.

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Shangary S, Wang S.

Annu Rev Pharmacol Toxicol. 2009;49:223-41. doi: 10.1146/annurev.pharmtox.48.113006.094723. Review.

20.

Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.

Barakat K, Mane J, Friesen D, Tuszynski J.

J Mol Graph Model. 2010 Feb 26;28(6):555-68. doi: 10.1016/j.jmgm.2009.12.003. Epub 2009 Dec 14.

PMID:
20056466
Items per page

Supplemental Content

Write to the Help Desk